Thursday, October, 21, 2021 01:25:55

The collaboration aims to develop novel companion diagnostics and offer tools to shift to a more personalized treatment approach.

Foundation Medicine and Bayer AG have recently announced a global partnership for developing and commercializing NGS-based companion diagnostics. This agreement enables partnership across approved therapies and several oncology drug candidates developed by Bayer and covers the complete portfolio of tests from Foundation Medicine, including FoundationOne®CDx.

Seemingly, the first project is to develop a companion diagnostic for larotrectinib, the first and only TRK inhibitor which is approved in the U.S. as a new tumor- agnostic treatment strategy for patients having TRK fusion cancer across all solid tumors.

According to Head of the Oncology Strategic Business Unit at Bayer and Member of the Executive Committee of Bayer’s Pharmaceuticals Division, Robert LaCaze, this collaboration with Foundation Medicine aims to develop novel companion diagnostics and offer tools to shift to a more personalized treatment approach.

The wider collaboration with Foundation Medicine and the development of a companion diagnostic for larotrectinib is a vital step forward, towards extending access to identifying and testing the right treatment options for cancer and patients, LaCaze said.

The partnership between Foundation Medicine and Bayer would develop several companion diagnostics including a companion diagnostic for larotrectinib, Chief Executive Officer of Foundation Medicine, Cindy Perettie also confirmed. It is vital that patients get broad inclusive genomic profiling at early diagnosis of late stage cancer to determine if they are entitled for these medicines, she mentioned.

For the uninitiated, FoundationOne CDx is a future generation sequencing-based in vitro diagnostic device for detecting substitutions, copy number alterations, deletion and insertion alterations in 324 genes and specific gene rearrangements. It also helps detect genomic signatures including tumor mutational burden and microsatellite instability using DNA secluded from formalin-fixed paraffin embedded (FFPE) specimens of tumor tissue.

Along with this, FoundationOne CDx is designed to offer tumor mutation profiling which is to be used by competent health care experts in line with expert guidelines in oncology for patients whavingith solid malignant neoplasms.

Source Credit: